Recombinant hepatitis B triple antigen vaccine: Hepacare

Area of Science:

• Hepatitis B research
• Vaccinology
• Immunology

Background:

• Hepatitis B virus infection is a global public health concern.
• Current hepatitis B vaccines are widely used but fail to elicit protective antibody responses in 5-10% of healthy individuals.
• Non-responsiveness and hypo-responsiveness to existing vaccines pose a challenge for achieving herd immunity.

Purpose of the Study:

• To evaluate the efficacy of a novel triple-antigen hepatitis B vaccine (Hepacare) in overcoming non-responsiveness and hypo-responsiveness.
• To assess the potential of Hepacare for individuals requiring rapid protection against hepatitis B.

Main Methods:

• Development of a novel triple-antigen vaccine incorporating pre-S1 and -S2 hepatitis B surface antigen components.
• Administration of the triple-antigen vaccine to individuals identified as non-responders or hypo-responders to single-antigen vaccines.

Main Results:

• The triple-antigen vaccine demonstrated effectiveness in a significant number of individuals who were previously non-responsive or hypo-responsive.
• Hepacare successfully induced protective immune responses in a notable proportion of the target population.

Conclusions:

• The novel triple-antigen hepatitis B vaccine (Hepacare) offers a promising solution for individuals with suboptimal responses to current vaccines.
• This vaccine has the potential to improve hepatitis B prevention strategies, particularly for non-responders and those needing rapid protection.